ATE279208T1 - Verfahren und stoffe zur behandlung des prostatakarzinomes - Google Patents

Verfahren und stoffe zur behandlung des prostatakarzinomes

Info

Publication number
ATE279208T1
ATE279208T1 AT99918940T AT99918940T ATE279208T1 AT E279208 T1 ATE279208 T1 AT E279208T1 AT 99918940 T AT99918940 T AT 99918940T AT 99918940 T AT99918940 T AT 99918940T AT E279208 T1 ATE279208 T1 AT E279208T1
Authority
AT
Austria
Prior art keywords
substances
treatment
prostate carcinoma
prostatic
carcinoma
Prior art date
Application number
AT99918940T
Other languages
English (en)
Inventor
Christopher Allen Seid
Gurpreet Singh
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Application granted granted Critical
Publication of ATE279208T1 publication Critical patent/ATE279208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99918940T 1998-06-17 1999-04-30 Verfahren und stoffe zur behandlung des prostatakarzinomes ATE279208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/099,017 US6280742B1 (en) 1998-06-17 1998-06-17 Methods and materials for the treatment of prostatic carcinoma
PCT/US1999/009592 WO1999065521A1 (en) 1998-06-17 1999-04-30 Methods and materials for the treatment of prostatic carcinoma

Publications (1)

Publication Number Publication Date
ATE279208T1 true ATE279208T1 (de) 2004-10-15

Family

ID=22272063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918940T ATE279208T1 (de) 1998-06-17 1999-04-30 Verfahren und stoffe zur behandlung des prostatakarzinomes

Country Status (9)

Country Link
US (1) US6280742B1 (de)
EP (1) EP1087786B1 (de)
JP (1) JP2002518345A (de)
CN (1) CN1313775A (de)
AT (1) ATE279208T1 (de)
AU (1) AU771362B2 (de)
CA (1) CA2335337A1 (de)
DE (1) DE69921130D1 (de)
WO (1) WO1999065521A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012218A1 (en) * 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
WO2001035994A2 (en) * 1999-11-04 2001-05-25 Zonagen, Inc. Chitosan induced immunopotentiation
AU2001276831A1 (en) 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
AU2001273034A1 (en) 2000-06-26 2002-01-08 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
PL2382990T3 (pl) 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
KR100700418B1 (ko) * 2003-09-08 2007-03-29 한국원자력연구소 방사성물질-키토산 복합체를 함유하는 전립선암 치료용조성물 및 조성물 제조용 키트
CN1559614A (zh) * 2004-02-17 2005-01-05 浙江大学 一种多糖类纳米抗癌材料及其制备方法
EA018643B1 (ru) * 2004-02-23 2013-09-30 Цайтэн Чжан Раствор металлсодержащего хелатного полимера и его применение (варианты)
US20050281891A1 (en) * 2004-06-03 2005-12-22 Ecobio, Inc. Testosterone stimulant
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
RU2309740C1 (ru) 2006-08-03 2007-11-10 Исаак Григорьевич Гитлин Антиоксидант для профилактики заболеваний, связанных с окислительным стрессом, способ его получения, содержащий его гранулят и таблетированная или капсулированная форма на его основе
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
US8318472B2 (en) * 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
EP3960215B1 (de) * 2009-12-15 2024-10-16 Incept, LLC Implantate und biologisch abbaubare bezugsmarkierungen
JP2017504621A (ja) 2013-10-02 2017-02-09 ヴィヴェンティア バイオ インコーポレイテッド 抗ｅｐｃａｍ抗体及び使用方法
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015098733A1 (ja) 2013-12-25 2015-07-02 出光興産株式会社 酒類用金属担持ゼオライト及び酒類の製造方法
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
JPS5823847B2 (ja) 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1993010763A1 (en) 1991-11-26 1993-06-10 Jenner Technologies Antitumor vaccines
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
AU686660B2 (en) 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
EP0652014A1 (de) 1993-11-10 1995-05-10 National Institute Of Immunology Behandlung von Prostatahypertrophie
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
ATE223235T1 (de) 1994-09-23 2002-09-15 Zonagen Inc Chitosan induzierte verstärkung

Also Published As

Publication number Publication date
EP1087786B1 (de) 2004-10-13
CA2335337A1 (en) 1999-12-23
JP2002518345A (ja) 2002-06-25
EP1087786A1 (de) 2001-04-04
DE69921130D1 (de) 2004-11-18
US6280742B1 (en) 2001-08-28
AU771362B2 (en) 2004-03-18
US20010014334A1 (en) 2001-08-16
AU3673799A (en) 2000-01-05
WO1999065521A1 (en) 1999-12-23
CN1313775A (zh) 2001-09-19

Similar Documents

Publication Publication Date Title
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
WO2003027094A3 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
PL328858A1 (en) Immunogenous peptides
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
DE60228583D1 (de) Verfahren und materialien für die behandlung des testosteron-mangels bei männern
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties